Chlormethine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00888 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 93 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | lymph node cancer | KG + DL |
| 2 | relapsing-remitting multiple sclerosis | KG + DL |
| 3 | follicular lymphoma | KG + DL |
| 4 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 5 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 6 | lymphoid neoplasm | KG + DL |
| 7 | interdigitating dendritic cell sarcoma | KG + DL |
| 8 | chest wall lymphoma | KG + DL |
| 9 | subcutaneous panniculitis-like T-cell lymphoma | KG + DL |
| 10 | acute lymphoblastic leukemia (disease) | KG + DL |
| 11 | ovarian lymphoma | KG + DL |
| 12 | nasal cavity lymphoma | KG + DL |
| 13 | composite lymphoma | KG + DL |
| 14 | progressive transformation of germinal centers | KG + DL |
| 15 | AIDS-related primary central nervous system lymphoma | KG + DL |
| 16 | reticulum cell sarcoma | KG + DL |
| 17 | neoplasm of mature B-cells | KG + DL |
| 18 | breast lymphoma | KG + DL |
| 19 | methotrexate-associated lymphoproliferative disorders | KG + DL |
| 20 | tracheal lymphoma | KG + DL |
| 21 | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma | KG + DL |
| 22 | acquired secondary polycythemia | KG + DL |
| 23 | lymphoid hemopathy | KG + DL |
| 24 | retroperitoneal lymphoma | KG + DL |
| 25 | bladder lymphoma | KG + DL |
| 26 | eye lymphoma | KG + DL |
| 27 | congenital secondary polycythemia | KG + DL |
| 28 | small intestinal Burkitt lymphoma | KG + DL |
| 29 | ureteral lymphoma | KG + DL |
| 30 | mediastinal malignant lymphoma | KG + DL |
| 31 | colon adenocarcinoma | KG + DL |
| 32 | small intestinal mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 33 | breast mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 34 | thyroid gland mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 35 | tonsillar lymphoma | KG + DL |
| 36 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 37 | ALK-positive large B-cell lymphoma | KG + DL |
| 38 | follicular lymphoma, susceptibility to, 1 | KG + DL |
| 39 | myeloid leukemia | KG + DL |
| 40 | refractory plasma cell neoplasm | KG + DL |
| 41 | leukemoid reaction | KG + DL |
| 42 | heavy chain disease | KG + DL |
| 43 | plasma cell myeloma | KG + DL |
| 44 | primary organ-specific lymphoma | KG + DL |
| 45 | B-cell prolymphocytic leukemia | KG + DL |
| 46 | lung lymphoma | KG + DL |
| 47 | bladder transitional cell carcinoma | KG + DL |
| 48 | plasma cell neoplasm | KG + DL |
| 49 | malignant tumor of meninges | KG + DL |
| 50 | indolent plasma cell myeloma | KG + DL |
(Showing top 50 of 93 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.